| DIRECT COMPETITOR COMPARISON | |
| AGEN | AVXT.PK | DNDN | GSK | Industry | | Market Cap: | 65.96M | N/A | 3.41B | 97.52B | 107.08M | | Employees: | 80 | N/A | 198 | 99,003 | 59 | | Qtrly Rev Growth (yoy): | 31.00% | N/A | -3.80% | 14.90% | 19.70% | | Revenue (ttm): | 3.31M | N/A | 108.00K | 42.54B | 13.84M | | Gross Margin (ttm): | 100.00% | N/A | 100.00% | 76.27% | 66.58% | | EBITDA (ttm): | -24.94M | N/A | -74.09M | 16.77B | -12.25M | | Oper Margins (ttm): | -881.51% | N/A | -72,917.59% | 34.30% | -158.08% | | Net Income (ttm): | -26.79M | N/A | -196.49M | 7.64B | N/A | | EPS (ttm): | -0.366 | N/A | -1.915 | 2.99 | -0.31 | | P/E (ttm): | N/A | N/A | N/A | 12.87 | 17.08 | | PEG (5 yr expected): | N/A | N/A | N/A | 2.29 | 1.15 | | P/S (ttm): | 20.88 | N/A | 31013.15 | 2.27 | 9.82 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | -0.44% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 2.37% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.70% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.46% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.84% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.32% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 1.09% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 1.24% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | -0.45% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.22% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.63% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.92% | 97.52B | 12.87 | | Sanofi-Aventis | SNY | 36.29 | 1.06% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.94% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 1.39% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 2.27% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 1.21% | 48.04B | 4.53 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | GSK | | Pfizer Off 2% As 2010 Targets Miss; Posts Revised 2012 Targets
Tue 8:20pm -
at Barrons.com | | • | DNDN | | This Stock Has Tremendous Upside
Tue 1:30pm -
at Motley Fool | | • | GSK | | Bone Up On This Potential Blockbuster
Tue 11:58am -
at Motley Fool | | • | GSK | | Europe Launches Probe into Pharma Deals
Tue 10:52am -
at BusinessWeek | | • | GSK | | Germany Cancels Swine Flu Vaccines
Tue 10:52am -
at BusinessWeek | | • | GSK | | Glaxo considering job cuts at UK research center
Tue 10:41am -
AP | | • | DNDN | | 5-Star Stocks Poised to Pop: ISTA Pharmaceuticals
Tue 9:44am -
at Motley Fool | | • | GSK | | Biotech Deal-Making Crosses Borders as Capital Markets Slide
Tue 4:32am -
at Seeking Alpha | | • | GSK | | Dynavax starts hepatitis B trial
Mon, Feb 8 -
at bizjournals.com | | • | DNDN | | An Earnings Surprise of an Unusual Kind
Mon, Feb 8 -
at Motley Fool | | • | DNDN | | 4 Winning Biotechs For Your Portfolio: Senior Analyst
Mon, Feb 8 -
at CNBC | | • | DNDN | | Is Biotech Back?
Mon, Feb 8 -
CNBC | | • | DNDN | | [video] Is Biotech Back?
Mon, Feb 8 -
at CNBC | | • | AVXT.PK | | AVAX Technologies, Inc. Closes Bridge Financing
Wed, Dec 16 -
PR Newswire | | • | AVXT.PK | | AVAX TECHNOLOGIES INC Financials
Thu, May 7 -
EDGAR Online Financials | | • | AVXT.PK | | AVAX TECHNOLOGIES INC Files SEC form 8-K, Other Events
Thu, Mar 26 -
EDGAR Online | | • | AVXT.PK | | AVAX TECHNOLOGIES INC Files SEC form 8-K, Other Events
Thu, Mar 26 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 
0.035 (4.55%) 
Competitors
